Acorda Announces Departure of Michael Rogers
October 04 2016 - 6:00AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced
that Chief Financial Officer Michael Rogers has left the company.
David Lawrence, Acorda’s Chief of Business Operations, has assumed
the role of Chief, Business Operations and Principal Accounting
Officer. Andrew Hindman, Acorda’s Chief Business Development
Officer, has assumed responsibility for Financial Planning and
Analysis and Investor Relations. Mr. Rogers will serve as a
consultant to the Company through the end of the year as part of
this transition.
“We thank Mike for his many contributions to Acorda during his
tenure. He was a key part of the team responsible for the
acquisitions of Civitas and Biotie, which have helped position
Acorda as a leader in Parkinson’s disease therapeutic development,”
said Ron Cohen, M.D., President and CEO of Acorda Therapeutics.
“Mike has been commuting from Boston throughout his years at
Acorda, which has been challenging for him and his family. I’m
grateful for his dedication to the Company during this time.”
“I also want to thank Dave Lawrence and Andrew Hindman for
taking on additional responsibilities within the Company. Dave led
our accounting and finance teams for many years, and Andrew has a
strong financial background and long-standing relationships with
many of Acorda’s investors.”
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a
biotechnology company focused on developing therapies that restore
function and improve the lives of people with neurological
disorders.
Acorda has a pipeline of novel neurological therapies addressing
a range of disorders, including Parkinson’s disease, post-stroke
walking difficulties, migraine, and multiple sclerosis. Acorda
markets three FDA-approved therapies, including
AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
For more information, please visit the Company’s website
at: www.acorda.com.
Forward-Looking Statement
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: the ability to complete the Biotie
transaction on a timely basis; the ability to realize the benefits
anticipated from the Biotie and Civitas transactions, among other
reasons because acquired development programs are generally subject
to all the risks inherent in the drug development process and our
knowledge of the risks specifically relevant to acquired programs
generally improves over time; the ability to successfully integrate
Biotie’s operations and Civitas’ operations, respectively, into our
operations; we may need to raise additional funds to finance our
expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell
Ampyra (dalfampridine) Extended Release Tablets, 10 mg in the
U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of
unfavorable results from future studies of Ampyra or from our other
research and development programs, including CVT-301 or any other
acquired or in-licensed programs; we may not be able to complete
development of, obtain regulatory approval for, or successfully
market CVT-301, any other products under development, or the
products that we will acquire when we complete the Biotie
transaction; the occurrence of adverse safety events with our
products; delays in obtaining or failure to obtain and maintain
regulatory approval of or to successfully market Fampyra outside of
the U.S. and our dependence on our collaborator Biogen in
connection therewith; competition; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and
failure to comply with regulatory requirements could result in
adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this presentation are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this presentation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161004005521/en/
Acorda TherapeuticsJeff Macdonald,
914-326-5232jmacdonald@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024